. 2006 Feb 13;103(8):2892–2897. doi: 10.1073/pnas.0511065103

Table 1.

Percent survival at 48 h of tau-(1–441)-infected CGCs and cortical neurons under various treatments

Treatment	CGCs		Cortical neurons
Treatment	Lac-Z	Tau-(1–441)	Lac-Z	Tau-1(1–441)
—	100	51 ± 2.8	100	40 ± 3
z-VAD-fmk	95 ± 3.2	52 ± 4^**	97 ± 2	44 ± 2^**
Ad-Bcl2	92 ± 2.8	48 ± 4.7^**	92 ± 3.2	47 ± 2^**
MK-801	98 ± 1.7	92 ± 3.4^**	97 ± 2	100 ± 2.2^**
APV	93 ± 3.7	87 ± 3.7^**	95 ± 2.8	98 ± 2^**
Memantine	100 ± 2	98 ± 2.4^**	97 ± 3	97 ± 1.8^**
CNQX	95 ± 4	50 ± 4.2^**	95 ± 2	35 ± 3^**
GYKY52466	97 ± 3.7	48 ± 3.2^**	93 ± 4	38 ± 4^**

z-VAD-fmk, Z-Val-Ala-Asp fluoromethyl ketone (100 μM); MK-801 (10 μM); APV, 2-amino-5-phosphonovaleric acid (100 μM); memantine (10 μM); CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione, (40 μM); GYKY52466 (100 μM). Data are expressed as in Fig. 1A.

**, P < 0.01 compared with untreated tau-expressing neurons.